Lynn Stillman is a seasoned regulatory professional with over 25 years of experience across innovative pharmaceuticals, small molecules, biologics, biosimilars, and generics, gained in both industry and consultancy settings. She has held senior leadership roles overseeing regulatory, drug safety, medical, and quality assurance departments in global pharmaceutical companies and consulting firms. Demonstrates expertise in managing European and global cross-disciplinary teams through all stages of regulatory submissions, from pre-registration to post-approval activities.
Skilled in developing regulatory strategies for complex clinical development programs, including oncology, and in leading governance processes for major registration submissions and global regulatory interactions.

Andeleeb Al Mobaraq-Dahy is a Regulatory Affairs executive with extensive experience in shaping and executing global regulatory strategies across pharmaceutical and biotechnology sectors. With a pragmatic and results-driven approach, she has successfully guided regulatory activities from early clinical development through post-approval stages across diverse therapeutic areas, including Advanced Therapy Medicinal Products (ATMPs), biologics and small molecules. 
Andeleeb has a proven track record of leading regulatory interactions with major health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). She has spearheaded and managed complex regulatory submissions across the U.S. and EU regions. 
Recognized for her leadership in regulatory sciences, Andeleeb excels in cross-functional collaboration and ensuring regulatory alignment with corporate objectives while prioritizing patient-centered outcomes. She is passionate about accelerating drug development timelines through innovative regulatory strategies and fostering seamless engagement with global regulatory agencies. 
Before joining SSI Strategy, Andeleeb served as Vice President and Head of Global Regulatory Affairs at Disc Medicine. Prior to that, she held regulatory roles at Astellas, Sanofi/Genzyme and Sandoz/Novartis. 
She remains actively engaged in the regulatory affairs community, contributing to industry discussions and advancements in global drug development. 

Ingela Loell is a Scientific Editor at SSI Strategy with more than 10 years of experience in scientific and regulatory communication. Holding a Ph.D. in Rheumatology from Karolinska Institutet, she specializes in translating complex biomedical science into clear, structured content for biotech and pharmaceutical audiences. Her work includes thought leadership, regulatory intelligence, and scientific documentation, developed in close collaboration with subject matter experts. She also supports AI-enabled innovation initiatives focused on improving the quality and efficiency of scientific content development.